Antibody-drug conjugates, looking ahead to an emerging class of biotherapeutic

Pharmaceutical Technology

Volumn 36, Issue 1, 2012, Pages 42-47

  Ritter, Amy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRENTUXIMAB VEDOTIN; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VEDOTIN;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL KILLING; DRUG APPROVAL; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY;

EID: 84859028841     PISSN: 15432521     EISSN: 21507376     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. S. Webb, Pharma Interest Surges in Antibody Drug Conjugates, Nat. Biotechnol. online, DOI:10.1038/nbt0411-297, Apr. 8, 2011.
2. V. de Groot, Novel ADC Linker-Drug Technology for Next Generation ADC Products, presented at Peptalk-Protein Science Week (Cambridge Health Institute, San Diego, Jan. 10-14, 2011).
3. FDA, Label for Adcetris, BLA 125338, FDA Approved Drug Products: Drugs@FDA, accessed Dec. 20, 2011.
4. V.S. Goldmacher and Y.V. Kovtun, Ther. Deliv. 2 (3), 397-416 (2011).
5. F. Dosio, P. Brusa and L. Cattel, Toxins 3, 848-883 (2011).
6. H.A. Burris, Expert Opin. Biol. Ther. 11 (6), 807-819 (2011).
7. A. Beck et al., Discov. Med. 10 (53), 329-359 (2010).
8. S.V. Govindan and DM Goldenberg, Scientific World Journal 10, 2070-2089 (2010).
9. Junutula et al., Nat. Biotechnol. 26 (8), 925-932 (2008).
10. Junutula et al., Clin. Canc. Res. 16, 4769-4778 (2010).
11. A. Ritter Pharm. Tech. 35 (6), 36-39 (2011).
12. Zawada et al., Biotech. Bioeng. 108 (7), 1570-1578 (2011).